<DOC>
	<DOCNO>NCT00831506</DOCNO>
	<brief_summary>This study design confirm , healthy subject , lack clinically important pharmacokinetic interaction Dimebon , propose maximum commercial dose 20 mg TID ( administer every 8 hour ) , digoxin ( LanoxinÂ® ) 0.125 mg QD , sensitive P-gp substrate recommend FDA .</brief_summary>
	<brief_title>Dimebon ( PF-01913539 ) -Digoxin Drug-Drug Interaction Study In Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Huntington Disease</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<criteria>Healthy male and/or female subject age 18 55 year , inclusive ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test ) . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . A known history hypersensitivity previous intolerance Dimebon digoxin . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) disease clinical finding screen . Pregnant nursing woman ; woman childbearing potential ( WOCBP ) unwilling unable use acceptable method contraception outline protocol least 14 day prior first dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>digoxin dimebon drug-drug interaction study</keyword>
</DOC>